Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2011 Nov 10.
Published in final edited form as: DNA Repair (Amst). 2010 Nov 10;9(11):1209–1213. doi: 10.1016/j.dnarep.2010.08.006

Conservation of Functional Asymmetry in the Mammalian MutLα ATPase

Jennifer R Johnson a, Naz Erdeniz a, Megan Nguyen a, Sandra Dudley a, R Michael Liskay a,b
PMCID: PMC2970632  NIHMSID: NIHMS240556  PMID: 20864418

Abstract

The DNA mismatch repair (MMR) protein dimer MutLα is comprised of the MutL homologues MLH1 and PMS2, which each belong to the family of GHL ATPases. These ATPases undergo functionally important conformational changes, including dimerization of the NH2-termini associated with ATP binding and hydrolysis. Previous studies in yeast and biochemical studies with the mammalian proteins established the importance of the MutLα ATPase for overall MMR function. Additionally, the studies in yeast demonstrated a functional asymmetry between the contributions of the Mlh1 and Pms1 ATPase domains to MMR that was not reflected in the biochemical studies. We investigated the effect of mutating the highly conserved ATP hydrolysis and Mg2+ binding residues of MLH1 and PMS2 in mammalian cell lines. Amino acid substitutions in MLH1 intended to impact either ATP binding or hydrolysis disabled MMR, as measured by instability at microsatellite sequences, to an extent similar to MLH1 null mutation. Furthermore, cells expressing these MLH1 mutations exhibited resistance to the MMR-dependent cytotoxic effect of 6-thioguanine (6-TG). In contrast, ATP hydrolysis and binding mutants of PMS2 displayed no measureable increase in microsatellite instability or resistance to 6-TG. Our findings suggest that, in vivo, the integrity of the MLH1 ATPase domain is more critical than the PMS2 ATPase domain for normal MMR functions. These in vivo results are in contrast to results obtained previously in vitro that showed no functional asymmetry within the MutLα ATPase, highlighting the differences between in vivo and in vitro systems.

1. Introduction

DNA mismatch repair (MMR) is a highly conserved cellular function that corrects replication errors, signals apoptosis in response to certain DNA damaging agents, and suppresses homeologous recombination [1]. In cells compromised for MMR, mutation rates can increase by as much as 1000-fold [2]. In humans, germline mutations in certain MMR genes can cause increased cancer susceptibility, notably hereditary nonpolyposis colorectal cancer [3].

The process of mismatch repair is best understood in the bacterium Escherichia coli, where a minimal system was reconstituted in vitro [4]. MMR is initiated when a homodimer of the MutS protein recognizes and binds to a mismatch [5, 6]. Next, MutS recruits the MutL homodimer, which has been termed a “molecular matchmaker” as it couples mismatch recognition to downstream repair events, including strand discrimination, excision, and resynthesis [7].

Multiple MutL homologues exist in eukaryotes, each functioning as heterodimers [8, 9]. The predominant heterodimer involved in MMR is MutLα, which consists of MLH1 and PMS2 (PMS1 in yeast) [9]. Similar to MutL, MutLα interacts with multiple MMR components, including MutS homologues, the replication processivity factor PCNA, and the exonuclease EXO1 [1012].

The first described biochemical activity assigned to MutL and its homologues was an ATPase activity. Sequence analysis and determination of the crystal structure of the N-terminus assigned MutL to the GHL ATPase family, which also includes gyrase B and Hsp90 [13, 14]. All GHL members contain an ATPase domain composed of four highly conserved N-terminal motifs necessary for protein dimerization and function [14]. MutL was shown to undergo an ATPase cycle whereby ATP binding caused a conformational change leading to dimerization of the N-termini [13]. It was subsequently shown that ATP binding was necessary for recruitment and activation of downstream MMR components, including MutH and UvrD [15].

Unlike bacterial MutL, MutLα in eukaryotes exists as a heterodimer. The first study to address the consequences of individually mutating the components of MutLα supported a functional asymmetry in vivo in the contributions of the Mlh1 and Pms1 ATPase domains to MMR [16]. Together with a second in vivo study [17], the alanine substitutions impacting the ATPase domain of Mlh1 had a much greater impact on MMR-dependent mutation avoidance than the corresponding Pms1 mutations. In stark contrast, ATP binding and hydrolysis mutants of either human MLH1 or PMS2 both strongly compromised MutLα activity as determined by in vitro MMR assays [18, 19].

The apparent lack of functional asymmetry within MutLα suggested by the human in vitro studies is at odds with the asymmetry observed in budding yeast. This discrepancy could reflect a functional difference between the MutLα ATPase of yeast and human cells. Another explanation is that the yeast studies were in vivo while the human studies were conducted in vitro. To further probe the discrepancy, we stably expressed exogenous human WT or mutant forms of MLH1 or PMS2 in mouse cells null for either MLH1 or PMS2. We then assayed for repair efficiency by microsatellite instability at mono- and dinucleotide runs. In addition, we compared the MMR-dependent response to the methylation mimetic drug 6-thioguanine among the cell lines. We found that whereas ATP binding or hydrolysis mutants of MLH1 strongly impacted both MMR-dependent spell-checking and damage response functions, the equivalent mutants of PMS2 had no detectable impact on MMR. These results support a functional asymmetry between the ATPase domains of MLH1 and PMS2 and highlight the level of functional conservation between yeast and mammalian MutLα.

2. Materials and methods

2.1 Cell lines and media

MC2 Mlh1−/− and WT complemented cell lines were derived as described [20]. MLH1-E34A and MLH1-N38A cells were created by transfecting plasmids expressing MLH1-E34A and MLH1-N38A human MLH1 cDNA off the CMV promoter into Mlh1ko/ko mouse embryonic fibroblasts (MEFs). 20 µg linearized DNA was electroporated into 1×107 cells at 0.32 kV and 500 µF. Stably expressing transfectant colonies were selected using neomycin at 200 µg/mL.

C18 Pms2−/− and WT complemented cells were derived as described [21]. PMS2-E41A, and PMS2-N45A cells were created as above, only using PMS2-E41A and PMS2-N45A human PMS2 cDNA containing plasmids transfected into Pmsko/ko MEFs. Stably expressing transfectant clonal lines were selected using puromycin at 2 µg/mL.

All cell lines were maintained in DMEM supplemented with 10% BCS, 1xNEAA, and 50 µg/mL gentamycin sulfate and grown in a humidified incubator with 5% CO2.

For microsatellite analysis, cell lines were subcloned, passaged at 1:10 for two weeks, and then 300 cells were plated on 150 mm plates for colony formation. For each cell line, at least ten clones stably expressing the various MLH1 and PMS2 expression vectors were expanded and harvested for genomic DNA.

2.2 Plasmid construction

MLH1-E34A, and PMS2-E41A were constructed as described [18], only the cDNA containing the mutation was cloned into the expression vectors pCMV-neo (for MLH1) and pCMV-puro (for PMS2). MLH1-N38A and PMS2-N45A were created by site-directed mutagenesis (Stratagene) of pBluescript plasmids containing the MLH1 or PMS2 cDNA, according to manufacturer’s protocol. Primers containing the desired mutations were used for PCR with the plasmids as template: 5'CAAAGAGATGATTGAGGCCTGTTTAGATGCAAAATCC3' and 5'GGATTTTGCATCTAAACAGGCCTCAATCATCTCTTTG3' for MLH1-N38A and 5'GGTAAAGGAGTTAGTAGAAGCCAGTCTGGATGCATGCTGG3' and 5'CCAGCATGCATCCAGACTGGCTTCTACTAACTCCTTTACC3' for PMS2-N45A. The cDNAs were cloned into either pCMV-neo or pCMV-puro and mutations confirmed by sequencing.

2.3 Western blots

1×106 cells were lysed in 1x SDS sample buffer, heated at 95° for 5 min, and 50 µg total protein run on an 8% SDS-PAGE gel. The protein was transferred to a PDVF membrane and probed with mouse anti-human MLH1, PMS2, and MSH6 antibodies (BD Biosciences) at 1:1000, 1:500, and 1:2500. Membranes were probed with goat anti-mouse HRP secondary antibody (Jackson ImmunoResearch) at 1:1000. Bands were visualized using enhanced chemilumenescense (Perkin Elmer).

2.4 DNA preparation

Genomic DNA was prepared by trypsinizing cells, washing in PBS, and resuspending in DNA lysis buffer containg 10mM Tris pH 7.5, 10mM EDTA pH 8, 10mM NaCl, and 0.5% sarkosyl, plus 1 mg/mL proteinase K. Lysates were incubated overnight at 55° and the proteinase K was heat inactivated at 95° for 5 min.

2.5 Microsatellite instability analysis

Six loci containing dinucleotide (CA)n repeats of repeat length n=17–34 were utilized. DNA was diluted 1:10 and subjected to PCR using the following primers:

  • D4MIT27-F:5′GCACGGTAGTTTTTCCAGGA3′

  • D4MIT27-R:5′TGGTGGGCAGGCAATAGT3′

  • D19MIT41-F:5′AGCCCTCCACCCAGTTTC3′

  • D19MIT41-R:5′TCTGGGGAAAAAGGATGAGA 3′

  • D13MIT67-F:5′TTTCATGGAGTCGAGTATTTTGG 3′

  • D13MIT67-R:5′ATCTTGCATAGAACCTTTGGATG3′

  • D16MIT4-F:5′AGTTCCAGGCTACTTGGGGT3′

  • D16MIT4-R:5′GAGCCCTCATTGCAAATCAT3′

  • D17MIT123-F:5′CACAAGGAGGGAGCCTGTAG3′

  • D17MIT123-R:5′CACCGTAAGAGTCTAATAATAAGGGG3′

  • D13MIT139-F:5′AGAATAAGTCAAGGCTATGATGTGG3′

  • D13MIT139-R:5′TTGTTTGTTTGTTTGAAGTAGAACG 3′

PCRs were conducted using a Robocycler under the following conditions: 95°C 5 min, 64° 1 min, 72° 1 min, 95° 1 min, 62°/60°/58° 1 min, 72° 1 min, 95° 1 min, 56°/52° 1 min, 30 cycles of 95° 1 min, 52° 1 min, 72° 1 min, with a final extension of 72° 3 min. PCR products were loaded onto a 7% denaturing acrylamide gel. The DNA was transferred to a nitrocellulose membrane and hybridized using a biotin-labeled (CA)10 oligodeoxynucleotide. P-values were calculated using Fisher’s exact t-test on Prism v. 3.0 software.

Six loci containing (A)n runs of repeat length n=23–37 were analyzed. A universal system of fluorescently tagged M13 primers was used to label PCR products for analysis [22]. All forward primers contained a 5' M13 tail of the following sequence: 5'CACGACGTTGTAAAACGAC3'. Fluorescently labeled M13 forward primer was included to produce a 3-primer reaction resulting in amplification of the mononucleotide loci with a fluorescently labeled M13 end. PCR was carried out using the following primers to amplify the A run loci:

  • uPAR-F:5′CACGACGTTGTAAAACGACGCTCATCTTCGTTCCCTGTC3′

  • uPAR-R:5′GTTTCTTCATTCGGTGGAAAGCTCTGA3′

  • JH116-F:5′CACGACGTTGTAAAACGACCTCTGGGCATACCAGCTACTG3′

  • JH116-R:5′CTCCATCCTGTGAGGTTAAACACAT3′

  • 27A-F:5′CACGACGTTGTAAAACGACCTATTGGATAAGTATGAGGTACTG3′

  • 27A-R:5′GTTTCTTCACCATAGTGCTAGCAATCAAGTGG3′

  • 23A-F:5′CACGACGTTGTAAAACGACTTGCTGAATTGGTGAGCTTC3′

  • 23A-R:5′GTTTCTACGTCAAAAATCAATGTTAGG3′

  • M-BAT 26-F5′CACGACGTTGTAAAACGACTCACCATCCATTGCACAGTT3′

  • M-BAT 26-R:5′GTTTCTCTGCGAGAAGGTACTCACCC3′

  • M-BAT 37-F:5′CACGACGTTGTAAAACGACTCTGCCCAAACGTGCTTAAT3′

  • M-BAT 37-R:5′GTTTCTCCTGCCTGGGCTAAAATAGA3′

PCR conditions were as follows: 95° 5 min, 20 cycles of 94° 15 sec, 65° 20 sec (−1° per cycle), 72° 20 sec, 35 cycles of 92° 15 sec, 50° 15 sec, 72° 15 sec, and a final extension of 72° for 10 min. PCR products were subjected to fragment size analysis by the OHSU MMI Sequencing Core using an ABI Prism Sequencer and analyzed using Peak Scanner software.

2.6 6-TG colony formation assay

Cells were plated out onto 100 mm plates at a density of 300 or 500 cells per plate. After 24 hours, 6-thioguanine (Sigma) was added for 24 hours, the cells were washed and fresh media was added. 7–10 days after addition of 6-TG the media was removed and the plates were fixed in 25% ethanol, 50% methanol, 0.25% methylene blue to stain the colonies. Colonies with greater than 50 cells were counted. For each dose of 6-TG, three plates were analyzed, and the experiment was repeated three times. Results represent the average of three experiments.

3. Results and discussion

3.1 Generation of MLH1 and PMS2 ATPase mutant cell lines

To assess the effect of alanine substitutions within the ATPase domain of MLH1 and PMS2 on the function of mammalian MutLα, stable cell lines were generated by transfecting WT or mutant MLH1 or PMS2 human cDNA into spontaneously established Mlh1−/− or Pms2−/− mouse embryonic fibroblasts (MEFs) and selecting for stably expressing colonies. Two alanine subsitution mutations were examined, one at a residue critical for ATP hydrolysis (MLH1-E34A and PMS2-E41A) and one at a residue important for Mg2+ binding, which is necessary for coordination of ATP binding (MLH1-N38A and PMS2-N45A) [18, 19]. To ensure similar levels of protein expression among the cell lines, quantitative Western blots were performed using the MMR protein MSH6 as a loading control. We selected cell lines the expressed the ATPase mutants at a level similar to that of the corresponding WT protein expressing lines that showed full complementation. As seen in Figure 1, the MLH1 and PMS2 ATP hydrolysis and Mg2+ binding mutant proteins are expressed at approximately the same level as the corresponding exogenously expressed WT proteins.

Figure 1. Protein expression in MC2 and C18 parent and complemented cell lines.

Figure 1

Western blots of MC2 (Mlh1−/−) cells expressing WT MLH1, MLH1-E34A, and MLH1-N38A in the left panel and C18 (Pms2−/−) cells expressing WT PMS2, PMS2-E41A, and PMS2-N45A in the right panel. The MSH6 signal was used as a loading control. MC2 cells display reduced PMS2 expression, as PMS2 depends on MLH1 for protein stability [23].

3.2 Asymmetric microsatellite instability phenotypes of MutLα ATPase mutants

Once equal expression levels between the cognate cell lines were determined, we performed microsatellite instability assays. Cells were subcloned, passaged for two weeks, and plated out to establish individual clones. At least 10 clones per cell line were expanded, again tested for stable protein expression, and DNA prepared for PCR analysis. PCR was conducted using primers specific for di- or mononucleotide runs that had previously been established to show high instability in MMR-null cell lines [20, 23].

For the dinucleotide repeat analysis, the PCRs were run on a 7.5% acrylamide gel and analyzed for shifts. As seen in Table 1, the knockout cell lines for both Mlh1 (MC2) and Pms2 (C18) had a significantly higher frequency of dinucleotide repeat mutation than the WT complemented lines, with 11.1% for MC2 Mlh1-null cells and 2.2% for the MLH1 WT-expressing cells (p=0.001, Fisher’s t-test) and 12.9% and 1.5% for the C18 Pms2-null and PMS2 WT-expressing cells, respectively (p=0.001). These results are consistent with previous reports showing an increase in microsatellite instability when MMR is compromised [24]. Of interest, both MLH-E34A and MLH1-N38A showed a frequency of mutation that was equivalent to the MC2, Mlh1−/− cells. MLH1-E34A showed a frequency of 6.5% (p=0.015 vs WT) and MLH1-N38A had a frequency of 9% (p=0.003 vs WT). On the other hand, PMS2-E41A and PMS2-N45A had a frequency of mutation that was equal to the C18 + WT PMS2 complemented cell line (3% and 3.8%, p=0.68 and p=0.43 vs WT). These results suggest that at dinucleotide runs, the MLH1 ATPase mutants impact repair to a greater degree than the PMS2 mutants.

Table 1.

Microsatellite instability analysis at (CA)n repeats in MLH1 and PMS2 expressing cell lines.

Cell line #slips/total Frequency (%) p-value vs. WT p-value vs. null
MC2 Mlh1−/− 23/224 11.1 0.001
MC2 WT 8/360 2.2 0.001
MLH1-E34A 15/230 6.5 0.015 0.176
MLH1-N38A 12/132 9 0.003 0.58
C18 Pms2−/− 48/372 12.9 0.001
C18 WT 2/126 1.5 0.001
PMS2-E41A 4/132 3 0.68 0.007
PMS2-N45A 6/156 3.8 0.43 0.001

Next, for mononucleotide analysis, the PCR products were fluorescently tagged and subjected to fragment length analysis as described in Materials and Methods. As shown in Table 2, the MC2 Mlh1−/− and C18 Pms2−/− cells had a frequency of mononucleotide mutation significantly different than the WT complemented cells (19.7% and 13% vs 1.4% and 3.5%, p=0.002 and 0.01). MLH1-E34A had a frequency of slippage that was equivalent to the MC2 Mlh1−/− cells (12.5% p=0.007 vs WT), while the PMS2-E41A and PMS2-N45A cells had a mutation frequency that was similar to the PMS2 WT complemented line (2.1% p=0.69 and 3.6% p=1). The MLH1-N38A cells, however, displayed an “intermediate” phenotype, with 8.3% mutation. The mutation frequency of the MLH1-N38A cells was statistically different from both the complemented (p=0.05) and MC2 parent cell lines (p=0.02). Overall, the MLH1 ATPase mutants displayed a greater degree of instability at mononucleotide runs than the corresponding PMS2 mutants.

Table 2.

Microsatellite instability analysis at (A)n repeats in MLH1 and PMS2 expressing cell lines.

Cell line Slips Frequency (%) p-value vs. WT p-value vs. null
MC2 Mlh1−/− 17/86 19.7 0.0002
MC2 WT 1/74 1.4 0.0002
MLH1-E34A 16/128 12.5 0.007 0.2
MLH1-N38A 10/120 8.3 0.05 0.02
C18 Pms2−/− 16/124 13 0.01
C18 WT 4/114 3.5 0.01
PMS2-E41A 2/96 2.1 0.69 0.005
PMS2-N45A 4/110 3.6 1 0.017

Taken together, the mono- and dinucleotide MSI data showed that mutations disabling either the MLH1 ATP binding or hydrolysis functions impacted MMR-dependent mutation avoidance in vivo to a greater extent than the equivalent PMS2 mutants.

3.3 Asymmetric cytotoxic response to 6-thioguanine of MutLα ATPase mutants

MMR has been shown to be necessary to signal apoptosis in response to the SN1-type DNA methylation mimetic drug 6-TG [25]. To assess whether the ATPase mutations of MLH1 and PMS2 disrupt this MMR-dependent response, we compared 6-TG resistance between the MLH1 and PMS2 parental, WT complemented, and mutant expressing cell lines. As shown in Figure 2, the Mlh1-null MC2 cells showed increased resistance to 6-TG when compared to the WT complemented cells at all drug doses examined except the highest dose. Interestingly, the ATP hydrolysis and Mg2+ binding mutants of MLH1 displayed a 6-TG resistance level similar to the MC2 cells. At only the highest dose of 6-TG did the mutant the cells form colonies at a frequency equal to WT. It was previously shown that high doses of methylating agents trigger a cellular response independent of MMR [26].

Figure 2. 6-Thioguanine response in MLH1- and PMS2-expressing cells.

Figure 2

Cells were plated out and exposed to varying doses of 6-thioguanine for 24 hours. Colonies were stained with methylene blue and counted 8–10 days after plating. A) MC2, MLH1-WT, MLH1-E34A, or MLH1-N38A cells. B) C18, PMS2-WT, PMS2-E41A, or PMS2-N45A cells.

Similar to MC2, C18 cells were more resistant to 6-TG than PMS2 WT complemented cells, as shown in Figure 2. In contrast to the MLH1 ATPase mutants, the PMS2 ATP hydrolysis and Mg2+ binding mutants were indistinguishable from the WT complemented cells at all 6-TG doses. Therefore, the alanine substitutions of PMS2 that were intended to disrupt either ATP binding or hydrolysis had no effect on the MMR-dependent response to 6-TG.

The 6-TG response results for the MLH1 and PMS2 cell lines are consistent with the MSI results presented above. Both the MLH1 ATP hydrolysis and Mg2+ binding mutants disabled repair in vivo as measured by increased microsatellite instability. In addition, the MLH1 mutant cell lines were resistant to the cytotoxic effect of 6-TG, providing further evidence that mutations disabling the MLH1 ATPase domain disrupt overall MMR function. The PMS2 ATP hydrolysis and Mg2+ binding mutant cell lines did not display increased microsatellite instability, and showed no increased resistance to the cytotoxic effects of 6-TG, suggesting that, in vivo, PMS2 ATPase domain function is less critical for MMR function than MLH1 ATPase domain function.

3.4 Discussion

Previous work in yeast demonstrated an asymmetry in the contribution of the ATPase domains of Mlh1 and Pms1 to MMR function. Mutations impacting ATPase domain of Mlh1 impacted MMR-dependent mutation avoidance to a greater degree than equivalent the mutations of Pms1 [16, 17]. In contrast to yeast, mutations in the ATPase domain of human MLH1 and PMS2 affected repair equally, as measured by an in vitro repair assay [18, 19]. However, when we stably expressed equivalent ATP binding and hydrolysis mutations in mouse cells, we obtained results consistent with a functional asymmetry in the contribution of the ATPase domains of MLH1 and PMS2 to MMR. Specifically, our findings suggest that ATP binding and hydrolysis by MLH1 are more critical for MMR than ATP binding and hydrolysis by PMS2. Differential binding of ATP by MLH1 and PMS2 could account for this asymmetry, as it has been shown that yeast Mlh1 has a >10-fold higher affinity for ATP than does Pms1, and that Mlh1 appears to bind ATP before Pms1 [17]. In turn, because MutLα is responsible for recruiting downstream factors such as EXO1 and PCNA [11, 12], the ATPase domain of MLH1 may be more critical for this recruitment than the ATPase domain of PMS2.

Interestingly, the findings presented here and those of others [1619] show that the ATP binding and hydrolysis residues of PMS2 are critical for full MMR activity in vitro but dispensible in vivo. One possible explanation is that a factor, which can compensate for the ATPase activity of PMS2 in vivo, is not active in in vitro extracts. Another possibility is that the PMS2 ATPase is necessary for assembling an active MMR complex in vitro, whereas that complex is normally assembled in vivo, perhaps by the close association of MMR with the replication apparatus [11].

While the PMS2 ATPase domain does not appear to be critical for MMR-dependent mutation avoidance or the 6-TG damage response in vivo, it may be critical for certain MMR-dependent recombination functions. Previous analysis with yeast Pms1 ATPase mutants demonstrated that the Pms1 ATPase domain is more critical for repair of recombination intermediates than for repair of replication errors [27]. It would be interesting to analyze the contribution of the mammalian PMS2 ATPase domain to processing recombination intermediates. Further investigation into the MLH1 and PMS2 ATPase domains of MutLα should provide more insight into the biochemical basis for the observed functional asymmetry described here.

Acknowledgements

We thank Phouc Tran for critical reading of the manuscript. This work was supported by NIH awards R37 GM032741 and R01 GM032741 to R.M.L.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest

The authors declare that there are no conflicts of interest.

References

  • 1.Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chem Rev. 2006;106:302–323. doi: 10.1021/cr0404794. [DOI] [PubMed] [Google Scholar]
  • 2.Harfe BD, Jinks-Robertson S. Mismatch repair proteins and mitotic genome stability. Mutat Res. 2000;451:151–167. doi: 10.1016/s0027-5107(00)00047-6. [DOI] [PubMed] [Google Scholar]
  • 3.Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36:801–818. [PMC free article] [PubMed] [Google Scholar]
  • 4.Lahue RS, Au KG, Modrich P. DNA mismatch correction in a defined system. Science. 1989;245:160–164. doi: 10.1126/science.2665076. [DOI] [PubMed] [Google Scholar]
  • 5.Parker BO, Marinus MG. Repair of DNA heteroduplexes containing small heterologous sequences in Escherichia coli. Proc Natl Acad Sci U S A. 1992;89:1730–1734. doi: 10.1073/pnas.89.5.1730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Su SS, Modrich P. Escherichia coli mutS-encoded protein binds to mismatched DNA base pairs. Proc Natl Acad Sci U S A. 1986;83:5057–5061. doi: 10.1073/pnas.83.14.5057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sancar A, Hearst JE. Molecular matchmakers. Science. 1993;259:1415–1420. doi: 10.1126/science.8451638. [DOI] [PubMed] [Google Scholar]
  • 8.Li GM, Modrich P. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc Natl Acad Sci U S A. 1995;92:1950–1954. doi: 10.1073/pnas.92.6.1950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Prolla TA, Christie DM, Liskay RM. Dual requirement in yeast DNA mismatch repair for MLH1 and PMS1, two homologs of the bacterial mutL gene. Mol Cell Biol. 1994;14:407–415. doi: 10.1128/mcb.14.1.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Prolla TA, Pang Q, Alani E, Kolodner RD, Liskay RM. MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science. 1994;265:1091–1093. doi: 10.1126/science.8066446. [DOI] [PubMed] [Google Scholar]
  • 11.Umar A, Buermeyer AB, Simon JA, Thomas DC, Clark AB, Liskay RM, Kunkel TA. Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis. Cell. 1996;87:65–73. doi: 10.1016/s0092-8674(00)81323-9. [DOI] [PubMed] [Google Scholar]
  • 12.Tran PT, Simon JA, Liskay RM. Interactions of Exo1p with components of MutLalpha in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 2001;98:9760–9765. doi: 10.1073/pnas.161175998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ban C, Yang W. Crystal structure and ATPase activity of MutL: implications for DNA repair and mutagenesis. Cell. 1998;95:541–552. doi: 10.1016/s0092-8674(00)81621-9. [DOI] [PubMed] [Google Scholar]
  • 14.Dutta R, Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci. 2000;25:24–28. doi: 10.1016/s0968-0004(99)01503-0. [DOI] [PubMed] [Google Scholar]
  • 15.Polosina YY, Cupples CG. MutL: conducting the cell's response to mismatched and misaligned DNA. Bioessays. 32:51–59. doi: 10.1002/bies.200900089. [DOI] [PubMed] [Google Scholar]
  • 16.Tran PT, Liskay RM. Functional studies on the candidate ATPase domains of Saccharomyces cerevisiae MutLalpha. Mol Cell Biol. 2000;20:6390–6398. doi: 10.1128/mcb.20.17.6390-6398.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hall MC, Shcherbakova PV, Kunkel TA. Differential ATP binding and intrinsic ATP hydrolysis by amino-terminal domains of the yeast Mlh1 and Pms1 proteins. J Biol Chem. 2002;277:3673–3679. doi: 10.1074/jbc.M106120200. [DOI] [PubMed] [Google Scholar]
  • 18.Tomer G, Buermeyer AB, Nguyen MM, Liskay RM. Contribution of human mlh1 and pms2 ATPase activities to DNA mismatch repair. J Biol Chem. 2002;277:21801–21809. doi: 10.1074/jbc.M111342200. [DOI] [PubMed] [Google Scholar]
  • 19.Raschle M, Dufner P, Marra G, Jiricny J. Mutations within the hMLH1 and hPMS2 subunits of the human MutLalpha mismatch repair factor affect its ATPase activity, but not its ability to interact with hMutSalpha. J Biol Chem. 2002;277:21810–21820. doi: 10.1074/jbc.M108787200. [DOI] [PubMed] [Google Scholar]
  • 20.Buermeyer AB, Wilson-Van Patten C, Baker SM, Liskay RM. The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts. Cancer Res. 1999;59:538–541. [PubMed] [Google Scholar]
  • 21.Deschenes SM, Tomer G, Nguyen M, Erdeniz N, Juba NC, Sepulveda N, Pisani JE, Liskay RM. The E705K mutation in hPMS2 exerts recessive, not dominant, effects on mismatch repair. Cancer Lett. 2007;249:148–156. doi: 10.1016/j.canlet.2006.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Boutin-Ganache I, Raposo M, Raymond M, Deschepper CF. M13-tailed primers improve the readability and usability of microsatellite analyses performed with two different allele-sizing methods. Biotechniques. 2001;31:24–26. 28. [PubMed] [Google Scholar]
  • 23.Yao X, Buermeyer AB, Narayanan L, Tran D, Baker SM, Prolla TA, Glazer PM, Liskay RM, Arnheim N. Different mutator phenotypes in Mlh1- versus Pms2-deficient mice. Proc Natl Acad Sci U S A. 1999;96:6850–6855. doi: 10.1073/pnas.96.12.6850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Baker SM, Plug AW, Prolla TA, Bronner CE, Harris AC, Yao X, Christie DM, Monell C, Arnheim N, Bradley A, Ashley T, Liskay RM. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat Genet. 1996;13:336–342. doi: 10.1038/ng0796-336. [DOI] [PubMed] [Google Scholar]
  • 25.Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, Mace R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996;273:1109–1111. doi: 10.1126/science.273.5278.1109. [DOI] [PubMed] [Google Scholar]
  • 26.Stojic L, Cejka P, Jiricny J. High doses of SN1 type methylating agents activate DNA damage signaling cascades that are largely independent of mismatch repair. Cell Cycle. 2005;4:473–477. doi: 10.4161/cc.4.3.1528. [DOI] [PubMed] [Google Scholar]
  • 27.Welz-Voegele C, Stone JE, Tran PT, Kearney HM, Liskay RM, Petes TD, Jinks-Robertson S. Alleles of the yeast Pms1 mismatch-repair gene that differentially affect recombination- and replication-related processes. Genetics. 2002;162:1131–1145. doi: 10.1093/genetics/162.3.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES